Assignee
SYN X PHARMA INC
US·28 granted patents·2 pending applications·353 citations·filing 2001–2005
Top patents by PatentIndex Score
30 records- 0196US6890763B2Biopolymer marker indicative of disease state having a molecular weight of 1350 daltonsSYN X PHARMA INC·Filed 2001·Granted May 10, 2005·79 cites·6 claims
- 0286US6451547B1Process for differential diagnosis of Alzheimer's dementia and device thereforSYN X PHARMA INC·Filed 2001·Granted Sep 17, 2002·24 cites·13 claims
- 0384US7015004B2Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted Mar 21, 2006·6 cites·9 claims
- 0484US6602855B2Biopolymer marker indicative of disease state having a molecular weight of 1449 daltonsSYN X PHARMA INC·Filed 2001·Granted Aug 5, 2003·26 cites·9 claims
- 0583US6891154B2Amino acid sequence pattern matchingSYN X PHARMA INC·Filed 2002·Granted May 10, 2005·13 cites·16 claims
- 0682US7179606B2IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's diseaseSYN X PHARMA INC·Filed 2001·Granted Feb 20, 2007·23 cites·9 claims
- 0782US6620786B2Biopolymer marker indicative of disease state having molecular weight of 2937 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 16, 2003·19 cites·9 claims
- 0881US6627606B2Biopolymer marker indicative of disease state having a molecular weight of 1465 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·18 cites·9 claims
- 0981US6617308B2Biopolymer marker indicative of disease state having a molecular weight of 1865 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 9, 2003·18 cites·9 claims
- 1079US6620787B2Biopolymer marker indicative of disease state having a molecular weight of 2267 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 16, 2003·16 cites·9 claims
- 1174US6627608B2Biopolymer marker indicative of disease state having a molecular weight of 1206 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·15 cites·9 claims
- 1274US6593298B2Biopolymer marker indicative of disease state having a molecular weight of 1690 daltonsSYN X PHARMA INC·Filed 2001·Granted Jul 15, 2003·16 cites·9 claims
- 1372US6756476B2Biopolymer marker indicative of disease state having a molecular weight of 2021 daltonsSYN X PHARMA INC·Filed 2001·Granted Jun 29, 2004·14 cites·9 claims
- 1471US6599877B2Biopolymer marker indicative of disease state having a molecular weight of 1020 daltonsSYN X PHARMA INC·Filed 2001·Granted Jul 29, 2003·13 cites·9 claims
- 1569US7094549B2Fibronectin biopolymer marker indicative of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted Aug 22, 2006·2 cites·9 claims
- 1669US7052849B2Protein biopolymer markers predictive of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted May 30, 2006·7 cites·9 claims
- 1769US6627607B2Biopolymer marker indicative of disease state having a molecular weight of 1845 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·12 cites·9 claims
- 1868US7070945B2Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairmentSYN X PHARMA INC·Filed 2002·Granted Jul 4, 2006·7 cites·8 claims
- 1966US7074576B2Protein biopolymer markers indicative of alzheimer's diseaseSYN X PHARMA INC·Filed 2001·Granted Jul 11, 2006·1 cites·9 claims
- 2065US7132244B2Betaine/GABA transport protein biopolymer marker indicative of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted Nov 7, 2006·8 cites·9 claims
- 2164US7101680B2Method for detecting the presence of monomeric brain associated human glutamine synthetaseSYN X PHARMA INC·Filed 2001·Granted Sep 5, 2006·4 cites·3 claims
- 2262US7014854B2Method for retarding or precluding Alzheimer's dementiaSYN X PHARMA INC·Filed 2002·Granted Mar 21, 2006·5 cites·1 claims
- 2357US6998243B2Biopolymer marker indicative of disease state having a molecular weight of 1793 daltonsSYN X PHARMA INC·Filed 2001·Granted Feb 14, 2006·1 cites·9 claims
- 2455US7049397B2Biopolymer marker indicative of disease state having a molecular weight of 1211 daltonsSYN X PHARMA INC·Filed 2001·Granted May 23, 2006·4 cites·9 claims
- 2550US2005214874A1Diagnosis and treatment of early pre-Type-1 diabetes utilizing glial fibrillary acidic proteinSYN X PHARMA INC·Filed 2005·Application pending·0 cites
- 2648US7026129B2IG lambda biopolymer markers predictive of Alzheimers diseaseSYN X PHARMA INC·Filed 2001·Granted Apr 11, 2006·0 cites·9 claims
- 2747US7087435B2Biopolymer marker indicative of disease state having a molecular weight of 2753 daltonsSYN X PHARMA INC·Filed 2001·Granted Aug 8, 2006·0 cites·8 claims
- 2846US7097989B2Complement C3 precursor biopolymer markers predictive of type II diabetesSYN X PHARMA INC·Filed 2001·Granted Aug 29, 2006·1 cites·9 claims
- 2946US6890722B2HP biopolymer markers predictive of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted May 10, 2005·1 cites·9 claims
- 3045US2005130245A1Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteinsSYN X PHARMA INC·Filed 2004·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →